Drug
Lonigutamab
Lonigutamab: highest development phase Phase 1/2, developed by Acelyrin. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Acelyrin
Trials
| Drug | Phase | Indication |
|---|---|---|
| lonigutamab NCT05683496 | Phase 1/2 | Thyroid Eye Disease |
Latest
No recent events.
Follow Lonigutamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.